U.S. Markets open in 9 hrs 23 mins

Herbalife Ltd. (HLF)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
69.25+0.12 (+0.17%)
At close: 4:02PM EDT
People also watch
  • who do the democrats think they are fooling with their so called new better deal scam? it is their exact same old socialist agenda, nothing new about it at all, democrats really need to go visit Venezuela to see how socialism really works
  • 50 pgs sent today to FTC re: Herbalife HLF & Distributors Violations of Section III. & IV. of Stipulated Order for Permanent Injunction...
  • end of day action was interesting. The slide continues. First week in August should be glorious for shorts. $30k in 50 strike puts puts august-november
  • looks like my shorting more everyday in the 70's is over
  • Termites ate my whole house !
    The only thing left was hlf shake mix!
    Think about it!
  • RALLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    “KIT-302 has the potential to address the multi-billion dollar market for the treatment of osteoarthritis pain and hypertension with one drug that reduces patients’ risk of suffering a heart attack or stroke, while also reducing cost for payers. There is currently no single medication on the market that treats both osteoarthritis pain and hypertension and thus, KIT-302 will be the only NSAID indicated both to treat pain and to reduce the risk of heart attack, stroke and death.”

    Pain medications for osteoarthritis account for billions of dollars in annual sales globally. Most pain medications for osteoarthritis, including celecoxib which had global sales of $2.7 billion in 2014, are non-steroidal anti-inflammatory drugs (NSAIDs) which have the side effect of elevating blood pressure, and increasing the risk of heart attacks, strokes and death. Of the 27 million Americans who live with osteoarthritis, 13.5 million also suffer from hypertension, which also increases the risk of heart attack, stroke, and death.

  • I tried posting some bad news for HLF from China links today but YAHOO did'nt let me for some reasom
  • lower highs, lower lows everyday now
  • I wonder what it is like to hold 22,872,324 shares of HLF valued at 1.3 Billion and there are no buyers available. For every 1 cent drop Icahn drops $228,723 in value. Kind of mind boggling when you think about it.
  • HLF U.S. downlines falling apart, the pyramid has big holes in it all the way down.
  • HLF will be back in the 20's by Christmas 2017 and the single digits in late 2018
  • there is nothing HLF can do to hide their declining sales world wide so they are buying back shares and trying to hide declining earnings PER SHARE
  • HLF in a lot more trouble in China than NUS ever was.
  • HLF can not hide their big problems going on in China much longer.
  • Happens every quarter in front of earnings, articles come out, fear is spread, stock weakens, longs complain, same people make money.......Stock rebounds after earnings and shorts complain. People just need to learn how to play the stock movements. It's the same playbook every single quarter.
  • Here come the 60's :)
    I'll post the same for 50's 40's... single digits... LOL
  • Herbalife still the blood sucking disease infecting the Hispanic community in the U.S.
  • In fact it would be nice if Ackman and Icahn would both take their activist bull scam and both get out of my way.
  • also HLF cult clubs closing down much faster than new ones opening now